Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project.

Subjects

Subjects :

Antibodies, Monoclonal, Humanized
Anticholesteremic Agents economics
Anticholesteremic Agents pharmacology
Cholesterol, LDL blood
Cost-Benefit Analysis
Drug Approval
Eligibility Determination methods
Female
Humans
Male
Medication Therapy Management
Middle Aged
Registries statistics & numerical data
Treatment Outcome
United States
Antibodies, Monoclonal economics
Antibodies, Monoclonal pharmacology
Arteriosclerosis blood
Arteriosclerosis drug therapy
PCSK9 Inhibitors

Details

Language :

English

ISSN :

1097-6744

Volume :

195

Database :

MEDLINE

Journal :

American heart journal

Publication Type :

Report

Accession number :

29224643

Full Text :

https://doi.org/10.1016/j.ahj.2017.09.004